08:18 AM EDT, 04/02/2024 (MT Newswires) -- Avicanna Inc. ( AVCNF ) , a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products, on Tuesday reported a fourth-quarter net comprehensive loss of $2.4 million, or $0.02 per share, narrower than a loss of $7.8 million, or $0.09 per share, a year earlier.

Revenue for the quarter ended Dec. 31, 2023, was $6.1 million, up from $1.1 million a year earlier.

For the year ended Dec. 31, 2023, the company reported a net loss and comprehensive loss of $6.6 million, or $0.08 per share, narrower than a loss of $14.4 million, or $0.24 per share, in 2022.

Revenue for 2023 was $16.8 million, up from $4 million in 2022.